Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:INSM NASDAQ:RGC NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$110.02-0.9%$105.14$76.53▼$131.49$26.69B1.29943,949 shs616,421 shsINSMInsmed$102.56-1.5%$86.93$60.40▼$106.83$19.76B0.92.30 million shs1.43 million shsRGCRegencell Bioscience$14.50-2.4%$0.00$0.08▼$83.60$7.35B2.292.44 million shs641,295 shsSMMTSummit Therapeutics$26.20-5.2%$22.82$8.71▼$36.91$20.52B-1.013.76 million shs3.00 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-0.92%-2.54%+5.38%+11.40%+27.23%INSMInsmed-1.55%+4.46%+3.12%+41.41%+35.77%RGCRegencell Bioscience-2.42%-1.69%-77.11%+1,449,999,900.00%+1,449,999,900.00%SMMTSummit Therapeutics-5.18%+4.80%+29.96%+6.46%+181.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTXBioNTech1.4816 of 5 stars3.42.00.00.01.40.80.0INSMInsmed3.96 of 5 stars2.54.00.04.32.81.70.6RGCRegencell Bioscience0.2513 of 5 stars0.03.00.00.02.00.00.0SMMTSummit Therapeutics3.0858 of 5 stars4.43.00.00.02.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.83Moderate Buy$136.5824.14% UpsideINSMInsmed 3.00Buy$108.475.76% UpsideRGCRegencell Bioscience 0.00N/AN/AN/ASMMTSummit Therapeutics 2.79Moderate Buy$34.6732.32% UpsideCurrent Analyst Ratings BreakdownLatest RGC, BNTX, SMMT, and INSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$102.00 ➝ $108.007/16/2025BNTXBioNTechBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $126.007/10/2025BNTXBioNTechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$132.00 ➝ $133.007/8/2025INSMInsmedJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $111.007/1/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.007/1/2025SMMTSummit TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/25/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$138.006/16/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$145.00 ➝ $138.006/11/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $112.006/11/2025INSMInsmedMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.006/11/2025INSMInsmedRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.98B8.88N/AN/A$87.61 per share1.26INSMInsmed$363.71M53.49N/AN/A$1.60 per share64.10RGCRegencell BioscienceN/AN/AN/AN/A$0.02 per shareN/ASMMTSummit Therapeutics$700K27,797.08N/AN/A$0.53 per share49.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$719.92M-$3.40N/AN/AN/A-27.37%-3.94%-3.41%8/4/2025 (Estimated)INSMInsmed-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)RGCRegencell Bioscience-$4.30MN/A0.00∞N/AN/AN/AN/AN/ASMMTSummit Therapeutics-$221.32M-$0.34N/AN/AN/AN/A-62.87%-51.61%8/5/2025 (Estimated)Latest RGC, BNTX, SMMT, and INSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025INSMInsmed-$1.31N/AN/AN/AN/AN/A8/5/2025Q2 2025SMMTSummit Therapeutics-$0.10N/AN/AN/AN/AN/A8/4/2025Q2 2025BNTXBioNTech-$1.38N/AN/AN/A$161.26 millionN/A5/8/2025Q1 2025INSMInsmed-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.0110.1810.02INSMInsmed11.385.865.44RGCRegencell BioscienceN/AN/AN/ASMMTSummit TherapeuticsN/A10.6310.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%INSMInsmedN/ARGCRegencell Bioscience0.13%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%INSMInsmed3.00%RGCRegencell Bioscience2.00%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech6,772240.39 million194.24 millionOptionableINSMInsmed1,271189.71 million184.02 millionOptionableRGCRegencell Bioscience10N/AN/AN/ASMMTSummit Therapeutics110742.67 million112.14 millionOptionableRGC, BNTX, SMMT, and INSM HeadlinesRecent News About These CompaniesPrincipal Financial Group Inc. Has $4.75 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT)July 18 at 3:15 AM | marketbeat.comSMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law FirmJuly 17 at 10:53 AM | tmcnet.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJuly 17 at 10:00 AM | prnewswire.comSummit Therapeutics (NASDAQ:SMMT) Shares Up 9% - Still a Buy?July 16 at 1:00 PM | marketbeat.comFlorida Financial Advisors LLC Purchases Shares of 12,945 Summit Therapeutics PLC (NASDAQ:SMMT)July 15, 2025 | marketbeat.comSMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law FirmJuly 14, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJuly 12, 2025 | prnewswire.com12,025 Shares in Summit Therapeutics PLC (NASDAQ:SMMT) Purchased by U.S. Capital Wealth Advisors LLCJuly 12, 2025 | marketbeat.comSummit Therapeutics Inc. (SMMT) Stock Price Today - WSJJuly 10, 2025 | wsj.comSummit Therapeutics (NASDAQ:SMMT) Trading 7.6% Higher - Here's WhyJuly 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTJuly 7, 2025 | prnewswire.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's WhyJuly 7, 2025 | marketbeat.comSMMT Stock Gains on Rumored Licensing Talks With AstraZenecaJuly 7, 2025 | zacks.comSummit Therapeutics Inc. (SMMT) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.com2 Soaring Stocks With More Upside Potential to Buy and HoldJuly 4, 2025 | fool.comAstraZeneca in talks with Summit for over $15 billion license dealJuly 4, 2025 | thepharmaletter.comTSummit, AstraZeneca in talks over $15 billion partnership deal, Bloomberg News reportsJuly 3, 2025 | msn.comSummit Therapeutics Shares Climb Amid Rumored $15B Deal Talks with AstraZenecaJuly 3, 2025 | msn.comSummit said to be in talks with Astra to license potential rival for Merck’s KeytrudaJuly 3, 2025 | msn.comWhy Summit Therapeutics Stock Soared 8% Higher TodayJuly 3, 2025 | fool.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.3% - Should You Sell?July 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRGC, BNTX, SMMT, and INSM Company DescriptionsBioNTech NASDAQ:BNTX$110.02 -1.02 (-0.92%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$110.45 +0.43 (+0.39%) As of 07/18/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Insmed NASDAQ:INSM$102.56 -1.61 (-1.55%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$102.74 +0.17 (+0.17%) As of 07/18/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Regencell Bioscience NASDAQ:RGC$14.50 -0.36 (-2.42%) As of 07/18/2025 04:00 PM EasternRegencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.Summit Therapeutics NASDAQ:SMMT$26.20 -1.43 (-5.18%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$26.36 +0.16 (+0.60%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
